A.R.T. Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

A.R.T. Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-9,566	Closed	-$409K	–	771
2019 Q4	$409K	Sell	9,566 -17,800	-65%	-$734K	0.02%	920
2019 Q3	$1.17M	Buy	+27,366	New	+$1.49M	0.06%	483
2017 Q4	–	Sell	-47,245	Closed	-$2.52M	–	1613
2017 Q3	$2.52M	Buy	+47,245	New	+$2.8M	0.13%	211
2017 Q1	–	Sell	-3,400	Closed	-$239K	–	1660
2016 Q4	$239K	Buy	+3,400	New	+$241K	0.01%	1009
2016 Q2	–	Sell	-6,153	Closed	-$389K	–	1582
2016 Q1	$389K	Buy	6,153 +3,100	+102%	+$203K	0.02%	953
2015 Q4	$342K	Buy	+3,053	New	+$305K	0.02%	1004
2015 Q3	–	Sell	-18,493	Closed	-$1.89M	–	1544
2015 Q2	$1.89M	Buy	+18,493	New	+$1.44M	0.06%	470

Other funds holding RARE

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

A.R.T. Advisors's RARE Position: Q1 2020 in Review

A.R.T. Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2020, closing a stake of 9,566 shares — an estimated $409K sold.

A.R.T. Advisors first reported a position in RARE in Q2 2015 and held it in 7 quarters. The position peaked at $2.52M in Q3 2017. 174 funds tracked by Wall St. Rank hold RARE as of Q1 2020.

A.R.T. Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 9,566 Ultragenyx Pharmaceutical shares in Q1 2020, an estimated $409K.
A.R.T. Advisors first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and held it in 7 quarters.
A.R.T. Advisors's Ultragenyx Pharmaceutical position peaked at $2.52M in Q3 2017.
174 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.